Log In
BCIQ
Print this Print this
 

PF-06671008

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody against P-cadherin (CDH3) and CD3 developed using Dual-Affinity Re-Targeting (DART) technology
Molecular Target P-cadherin (CDH3) ; CD3
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today